



Stabilis



Tobramycin sulfate



Tradename

Bactob	India
Beltob	India
Bramicil	Italy
Brulamycin	Hungary, Malaysia, Slovenia
Eltol	India
Fytobra	India
Gernebcin	Germany
Komitob	India
Nebcin	Egypt, Great Britain, Greece, New Zealand, Saudi Arabia, United Arab Emirates
Nebcina	Denmark, Morocco, Norway, Sweden
Nebcine	France, Morocco, Slovenia
Nebicina	Italy
Obracin	Belgium, Luxembourg, Netherlands, Switzerland
Tobracin	Brazil, Egypt, Saudi Arabia
Tobramicina	Argentina, Brazil, Chile, Colombia, Ecuador, Italy, Portugal, Spain
Tobramina	Brazil
Tobramycin	Australia, Canada, Germany, Great Britain, Ireland, Norway, Saudi Arabia, United States of America
Tobramycine	France, Ireland, Netherlands
Tobrasix	Austria
Tobrazid	Germany



Stability in solutions

PVC		1,2 mg/ml	-20°C		28			565
PVC		1,2 mg/ml	25°C		48			434
PVC		1,2 mg/ml	4°C		48			434
PVC		1 & 10 mg/ml	25°C		3			13
PVC		1 & 10 mg/ml	5°C		14			13
PVC		3,2 mg/ml	-20°C		30			575

		0,95 mg/ml	23°C		7			1704
		0,95 mg/ml	4°C		30			1704
		40 mg/ml	25°C		60			709
		40 mg/ml	4°C		60			709
		30 mg/ml	22°C-23°C		48			639
		0,5 & 5 mg/ml	25°C		24			604
		0,5 & 5 mg/ml	4°C		10			604



Stability of mixtures

		3,2 mg/ml	25°C		Filgrastim : 40 µg/ml	4		104
		0,8 mg/ml	25°C		Ofloxacin : 2 mg/ml	48		889
		1 mg/ml	25°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		0,2 & 0,8 mg/ml	25°C		Aztreonam : 10 & 20 mg/ml	48		19
		0,2 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19
		0,2 & 0,8 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19
		1 mg/ml	4°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
		1,2 mg/ml	-20°C		Clindamycin phosphate : 9 mg/ml	28		565
		1,2 mg/ml	-20°C		Clindamycin phosphate : 9 mg/ml	14		565
		0,008 mg/ml	24°C		Ceftazidime : 0,125 mg/ml	16		2369
		0,008 mg/ml	37°C		Ceftazidime : 0,125 mg/ml	8		2369
		0,80 mg/ml	23°C		Linezolid : 1,80 mg/ml	1		2353
		0,80 mg/ml	4°C		Linezolid : 1,80 mg/ml	7		2353



Compatibility


























































		336
 		307
		3201
		3









		Tobramycin sulfate : 0.8 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Tobramycin sulfate : 5 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Tobramycin sulfate Amoxicillin sodium		3527
		Tobramycin sulfate Amoxicillin sodium / clavulanic acid		3545
		Tobramycin sulfate : 40 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Tobramycin sulfate : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Tobramycin sulfate : 5 mg/ml Amsacrine : 1 mg/ml		253
		Tobramycin sulfate : 5 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Tobramycin sulfate : 21 mg/ml Azithromycine : 2 mg/ml		1800
		Tobramycin sulfate : 0.2 & 0.8 mg/ml Aztreonam : 10 & 20 mg/ml		19
		Tobramycin sulfate : 5 mg/ml Aztreonam : 40 mg/ml		99
		Tobramycin sulfate : 5 mg/ml Bivalirudin : 5 mg/ml		1713
		Tobramycin sulfate : 40 mg/ml Caffeine : 10 mg/ml		3964
		Tobramycin sulfate : 1 mg/ml Calcium gluconate : 33 mg/ml		503
		Tobramycin sulfate Calcium gluconate		3644
		Tobramycin sulfate : 5 mg/ml Calcium gluconate : 16 mg/ml		503
		Tobramycin sulfate : 5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Tobramycin sulfate Cefamandole nafate		3546
		Tobramycin sulfate Cefamandole nafate : 2 >> 100 mg/ml		612
		Tobramycin sulfate : 6 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Tobramycin sulfate Cefepime dihydrochloride		3548
		Tobramycin sulfate : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Tobramycin sulfate : 0.8 mg/ml Cefoperazone sodium : 10 & 40 mg/ml		1206
		Tobramycin sulfate Cefoperazone sodium		3544
		Tobramycin sulfate Cefpirome sulfate		3677
		Tobramycin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249

		Tobramycin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Tobramycin sulfate : 6 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Tobramycin sulfate Ceftazidime		3883
		Tobramycin sulfate : 0.008 mg/ml Ceftazidime : 0.125 mg/ml		2369
		Tobramycin sulfate Ceftazidime		3543
		Tobramycin sulfate : 6 mg/ml Ceftazidime : 125 mg/ml		2141
		Tobramycin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Tobramycin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Tobramycin sulfate Ceftobiprole medocaril sodium		4650
		Tobramycin sulfate : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Tobramycin sulfate Ceftriaxone disodium		3523
		Tobramycin sulfate Cefuroxime sodium		3687
		Tobramycin sulfate : 1 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Tobramycin sulfate : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Tobramycin sulfate : 1,6 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
		Tobramycin sulfate : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Tobramycin sulfate Cisplatin		3578
		Tobramycin sulfate : 12 mg/ml Clindamycin phosphate : 90 mg/ml		639
		Tobramycin sulfate Clindamycin phosphate		3526
		Tobramycin sulfate : 40 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Tobramycin sulfate : 10 mg/ml Defibrotide : 8 mg/ml		3728
		Tobramycin sulfate : 5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Tobramycin sulfate : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Tobramycin sulfate : 5 mg/ml		1415
		Tobramycin sulfate : 5 mg/ml		301
		Tobramycin sulfate : 10 & 40 mg/ml		999
		Tobramycin sulfate : 10 mg/ml		316

	Tobramycin sulfate : 2.4 & 40 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Tobramycin sulfate : 0,05 mg/ml		4445
	Tobramycin sulfate Dimenhydrinate		2087
	Tobramycin sulfate : 5 mg/ml Doripenem : 5 mg/ml		2262
	Tobramycin sulfate : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Tobramycin sulfate : 0.8 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Tobramycin sulfate : 5 mg/ml Eravacycline : 0,6 mg/ml		4434
	Tobramycin sulfate Erythromycin lactobionate		3674
	Tobramycin sulfate : 0.8 mg/ml Esmolol hydrochloride : 10 mg/ml		384
	Tobramycin sulfate : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Tobramycin sulfate : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Tobramycin sulfate : 10 mg/ml Fentanyl citrate : 50 µg/ml		63
	Tobramycin sulfate : 1.6 mg/ml Filgrastim : 40 µg/ml		104
	Tobramycin sulfate : 5 mg/ml Filgrastim : 30 µg/ml		244
	Tobramycin sulfate Flucloxacillin sodium		3522
	Tobramycin sulfate : 8 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
	Tobramycin sulfate : 40 mg/ml Fluconazole : 2 mg/ml		496
	Tobramycin sulfate : 5 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Tobramycin sulfate Heparin sodium		3540
	Tobramycin sulfate : 40 mg/ml		673
	Tobramycin sulfate : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
	Tobramycin sulfate : 5 mg/ml Fosfomycin : 30 mg/ml		4055
	Tobramycin sulfate : 5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Tobramycin sulfate : 40 mg/ml	RL	4603
	Tobramycin sulfate : 8 mg/ml Furosemide : 1 mg/ml		1232
	Tobramycin sulfate : 1,6 mg/ml Furosemide : 0,8 mg/ml		367
	Tobramycin sulfate : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423

		Tobramycin sulfate : 0.8 mg/ml Heparin sodium : 50 UI/ml	∅	317
		Tobramycin sulfate : 5 mg/ml Hetastarch : 60 mg/ml		1721
		Tobramycin sulfate : 0.8 mg/ml Hetastarch : 60 mg/ml		472
		Tobramycin sulfate : 0.8 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Tobramycin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml		1745
		Tobramycin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml		494
		Tobramycin sulfate : 1.6 & 2 mg/ml Insulin : 0.2 UI/ml		129
		Tobramycin sulfate : 5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Tobramycin sulfate : 40 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Tobramycin sulfate : 0.8 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Tobramycin sulfate : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Tobramycin sulfate : 0,80 mg/ml Linezolid : 1,80 mg/ml		2353
		Tobramycin sulfate : 5 mg/ml Linezolid : 2 mg/ml	∅	1925
		Tobramycin sulfate : 0.8 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Tobramycin sulfate : 5 mg/ml Melphalan : 0.1 mg/ml		169
		Tobramycin sulfate : 40 mg/ml Meropenem : 50 mg/ml		4389
		Tobramycin sulfate : 40 mg/ml Meropenem : 50 mg/ml		4319
		Tobramycin sulfate : 0.8 mg/ml Metronidazole : 5 mg/ml	∅	1035
		Tobramycin sulfate Metronidazole		3594
		Tobramycin sulfate : 10 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Tobramycin sulfate : 1.6 >> 2.4 mg/ml Morphine sulfate : 1 mg/ml		406
		Tobramycin sulfate : 0.8 mg/ml Morphine sulfate : 1 mg/ml		405
		Tobramycin sulfate : 40 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Tobramycin sulfate : 0.8 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Tobramycin sulfate : 0,8 mg/ml Ofloxacin : 2 mg/ml	∅	889
		Tobramycin sulfate : 5 mg/ml Oritavancin : 0.8 >>> 2 mg/ml		3152

		Tobramycin sulfate Pantoprazole sodium		2090
		Tobramycin sulfate : 40 mg/ml Paracetamol : 10 mg/ml		4742
		Tobramycin sulfate : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Tobramycin sulfate : 1.6 >> 2.4 mg/ml Pethidine hydrochloride : 10 mg/ml		406
		Tobramycin sulfate : 0.8 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Tobramycin sulfate Piperacillin sodium		1168
		Tobramycin sulfate Piperacillin sodium / tazobactam		3586
		Tobramycin sulfate : 2 mg/ml Propofol		660
		Tobramycin sulfate : 5 mg/ml Propofol : 10 mg/ml		300
		Tobramycin sulfate : 5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Tobramycin sulfate : 40 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Tobramycin sulfate : 5 mg/ml Sargramostim : 10 µg/ml		335
		Tobramycin sulfate : 2,4 mg/ml Sodium bicarbonate : 40 mg/ml		3122
		Tobramycin sulfate : 5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Tobramycin sulfate : 40 mg/ml Tacrolimus : 1000 µg/ml		479
		Tobramycin sulfate : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Tobramycin sulfate Teicoplanine		3656
		Tobramycin sulfate : 5 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Tobramycin sulfate : 6 mg/ml Temocilline : 83.33 mg/ml		2231
		Tobramycin sulfate Temocilline		2296
		Tobramycin sulfate : 5 mg/ml Teniposide : 0.1 mg/ml		905
		Tobramycin sulfate : 0.8 mg/ml Theophylline : 4 mg/ml		317
		Tobramycin sulfate : 40 mg/ml Thiopental sodium : 25 mg/ml		3767
		Tobramycin sulfate : 5 mg/ml Thiotepa : 1 mg/ml		249
		Tobramycin sulfate Ticarcillin / clavulanic acid		3587
		Tobramycin sulfate Tigecycline		3332

	Tobramycin sulfate : 6 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Tobramycin sulfate : 0.16 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
	Tobramycin sulfate : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Tobramycin sulfate : 2 mg/ml Zidovudine : 4 mg/ml		337



Route of administration



References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
13	Journal	Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
19	Journal	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Journal	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Journal	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
129	Journal	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.

169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Journal	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Journal	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
285	Journal	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Journal	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Journal	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Journal	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.

337	Journal	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
367	Journal	Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119.
384	Journal	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Journal	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Journal	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Journal	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Journal	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
434	Journal	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
472	Journal	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	Journal	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
494	Journal	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Hosp Pharm 1992 ; 49: 836,838.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	Journal	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
503	Journal	Nahata MC, Durrell DE. Stability of tobramycin sulfate in admixtures with calcium gluconate. Am J Hosp Pharm 1985 ; 45: 1987-1988.
565	Journal	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.

575	Journal	Holmes CJ, Ausman RK, Kundsinn RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
612	Journal	Frable RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627.
639	Journal	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
660	Journal	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
673	Journal	Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN 1989 ; 13: 505-509.
709	Journal	Seitz DJ, Archambault JR, Brinck-Johnsen T. Stability of tobramycin sulfate in plastic syringes. Am J Hosp Pharm 1980 ; 37: 1614-1615.
889	Journal	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Journal	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Journal	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Journal	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Journal	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1168	Journal	Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H. Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin. Antimicrob Agents Chemother 1983 ; 23: 653-657.
1206	Journal	Frear RS. Cefoperazone-aminoglycoside incompatibility. Am J Hosp Pharm 1983 ; 40: 564.

1232	Journal	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Journal	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Journal	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1704	Journal	Xu QA, Trissel LA, Saenz A. Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags. Int J Pharm Compound 2002 ; 6: 152-154.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1745	Journal	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Health-Syst Pharm 1992 ; 49: 836-838.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	Journal	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800	Journal	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	Journal	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Journal	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Journal	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	Manufacturer	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2353	Journal	Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. Compatibility and stability of linezolid injection admixed with gentamicin sulfate and tobramycin sulfate. Int J Pharm Compound 2000 ; 4, 6: 476-479.
2369	Journal	Mason NA, Johnson CE, O'Brien MA. Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 1139 - 1142.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3122	Journal	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.

3152	Journal	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3201	Journal	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Journal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Manufacturer	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Journal	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3522	Manufacturer	Flucloxacillin - Summary of Product Characteristics. Actavis 2013
3523	Manufacturer	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	Manufacturer	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3527	Manufacturer	Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018
3540	Manufacturer	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3543	Manufacturer	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3544	Manufacturer	Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006
3545	Manufacturer	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3546	Manufacturer	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	Manufacturer	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3578	Manufacturer	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3586	Manufacturer	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Manufacturer	Ticarilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3594	Manufacturer	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013


3644	Manufacturer	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3656	Manufacturer	Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3677	Manufacturer	Cefpirome (Cefrom®) - Résumé des caractéristiques du produit Sanofi Aventis France 2008
3687	Manufacturer	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Journal	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	Manufacturer	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Journal	Côté K, Correard F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisolan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4445	Journal	Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D. Antibiotic compatibility and stability in a parenteral nutrition solution. Chemotherapy 1979 ; 25: 336-345.

4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Manufacturer	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis



Tobramycin sulfate









Stability of pharmaceutical preparations

		2400 mg Nebcin®	NaCl 0.45% >> 30 ml	25°C	?	195			3431
		2400 mg Nebcin®	NaCl 0.45% >> 30 ml	4°C	?	195			3431








Stability of mixtures

		NaCl 0.9% 2 ml	4°C	?	Salbutamol sulfate : Medicine bottle for injection ® = ? 2,5 mg=0		2960
			25°C		Colistin mesilate sodium : Medicine bottle for injection Colistin CF® 24		3440

		25°C		Colistin mesilate sodium : Medicine bottle for injection Colistin CF®	24		3mL	3440
		25°C		Colistin mesilate sodium : Medicine bottle for injection Colistin CF®	24		3mL	3440



Compatibility

			
	Tobramycin sulfate Dornase alfa		3472




References

	Type	Publication
2960	Journal	Gooch MD. Stability of albuterol and tobramycin when mixed for aerosol administration. Respiratory Care 1991 ; 36: 1387-1390.
3431	Journal	Law S. Stability of preservative-free tobramycin in half-normal saline. Can J Hosp Pharm 2001 ; 54, 3: 214-215.
3440	Journal	Wollstadt A, Krämer I, Kamin W. Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin. Pharmazie 2013 ; 68: 744-748.
3472	Journal	Krämer I, Schwabe A, Kamin W. Physikalisch-chemische Kompatibilität von Mischinhalationslösungen und Suspensionen zur simultanen feuchthinhalationstherapie bei Mukoviszidose Patienten. Krankenhauspharmazie 2007 ; 28, 5: 170-178.

Stabilis



Tobramycin sulfate



Stability of mixtures

	methylparaben 9,5 mg Propylparaben 3 mg Sodium benzoate 10 mg Sodium metabisulfite 7,5 mg Sodium phosphate 132,8 mg KCl 29,4 mg Na ₂ HPO ₄ 52, mg Purified water >> 10 ml Ampho-Moronal® 5 ml	2-8°C		Amphotericin B : powder ® = ? 500 mg Colistin sulfate : powder ® = ? 118 mg	180	3685


























































References

	Type	Publication
3685	Journal	Pfeifer C, Noll S, Gerecke H, Fassauer G, Jira T, Remane Y , Vogel J, Frontini R, Reinhardt R. A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements. EJHP 2017 ; 24:4 : 235-241



Dictionary

 Antibiotic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Polyvinyl chloride
 NaCl 0,9% or Glucose 5%	 Protect from light
 Day	 Light
 Hour	 Sodium chloride 0,9%
 Not specified	 Glucose 5%
 Ethylene vinyl acetate	 Polypropylen Syringe
 Water for Injection	 Polyisoprene elastomer
 Stability of mixtures	 Solvent
 Compound	 Glass
 None	 Dianéal® PD2 2.5% glucose (Baxter)
 Polyolefine	 Compatibility
 Compatible	 Precipitation after 1 hour
 Incompatible	 Chemical instability
 Unspecified incompatibility	 Immediate precipitation
RL Ringer's lactate solution	 Parenteral nutrition (with lipids)
 Parenteral nutrition (binary mixture)	 Precipitation after 7 hours
 specific solvent	 Precipitation after 15 minutes
 Color change after 4 hours	 Immediate instability of the emulsion
 Precipitation after 4 hours	 Immediate turbidity
 Route of administration	 Intravenous
 Intravenous infusion	 Intramuscular
 Subcutaneous infusion	 References
 aerosol	 Stability of pharmaceutical preparations
 Origine	 excipient

	Medicine bottle for injection		Polypropylene
	Oral solution		plastic bottle
	Dictionary		